http://www.officialwire.com/main.php?action=posted_news&rid=230951
Pipeline And Commercial Insight: Testosterone Replacement Therapy - Topical Formulations Drive Market Growth - New Market Report Published
New report provides detailed analysis of the Energy and Utilities market
Published on October 05, 2010
by Press Office
(Companiesandmarkets.com and OfficialWire)
LONDON, ENGLAND
The testosterone replacement therapy market grew with an impressive compound annual growth rate [CAGR]: 24.3% from 2005 to 2009 to reach $838m sales. While these drugs can reverse the symptoms of testosterone deficiency rather efficaciously, only an estimated 5% of affected people receive treatment.
Scope
* Patient potential analysis across the seven major markets
* Review of the key needs supported by key opinion leaders
* Current and future market dynamics in the seven major markets, including analysis and forecast for current leading brands
* R&D pipeline analysis with detailed profiles and forecasts of key agents, including Eli Lilly's Axiron (testosterone)
Highlights
Testosterone preparations come in a variety of formulations including injections and transdermal ones. While gels dominate the market in the US, in the EU there is a preference for injectables due to cost constraints.
The US is by far the largest market for testosterone replacement drugs, with sales in excess of $800m and accounting for almost 96% of the total sales value in 2009 and showing the strongest growth.
The deal with Eli Lilly is advantageous for Acrux. Axiron (testosterone) is the first metered dose transdermal system to reach this market. Driven by Eli Lilly's experience in the men's health arena and its marketing and sales resources, Axiron uptake which will become the leading drug in 2019.
Reasons to Purchase
* Understand patient population dynamics
* Gain insight into the unmet needs of current testosterone treatment and to what extent pipeline drugs will address these issues
* Identify licensing opportunities based on company portfolio and market needs
- Forums
- ASX - By Stock
- ACR
- a glowing endorsement for axiron
a glowing endorsement for axiron
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ACR (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.86M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 40561 | 5.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 141 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 40561 | 0.056 |
2 | 121190 | 0.054 |
1 | 37735 | 0.053 |
1 | 168669 | 0.052 |
4 | 369539 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.057 | 141 | 1 |
0.058 | 17257 | 1 |
0.060 | 1337 | 2 |
0.061 | 100000 | 1 |
0.062 | 116100 | 2 |
Last trade - 10.00am 15/10/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
Day chart unavailable
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online